A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IBC-Ab002 in Persons with Early Alzheimer's Disease

Subjects must meet all the following inclusion criteria to be eligible to participate in the study. 1. Age range: 50-80 years of age at the Screening visit. 2. Diagnosis of early AD based on the NIA-AA Research Framework criteria, regardless of APOE gene status a. Biomarker classification A+T+N+ or A+T+N- based upon Screening CSF profile consistent with AD defined by either of the following criteria: i. CSF Aβ42 < 1000 pg/mL and pTau181 > 19 pg/mL ii. CSb. AD Clinical Stage 3 or 4 based on the National Institute on Aging and Alzheimer's Association (NIA-AA) Research Framework criteria i. Have a Mini-Mental State Examination (MMSE) score at Screening between 20-26 inclusive. ii. Clinical Dementia Rating Scale (CDR) global score at Screening of 0.5 or 1 with memory box score > 1.0. 3. Able to speak, read and write the local language fluently. 4. With respect to symptomatic treatment for Alzheimer’s disease, subjects should either be: a. Not treated with any approved treatments for AD with a reasonable expectation that, based on the course of illness, need for treatment is not imminent and the patient should not be initiated on treatment for the length of the study, OR b. Stabilized on an approved medication(s) other than anti-Ab antibodies for the treatment of AD for at least 3 months prior to Baseline. The dose of the AD treatment should remain the same after entering the study. 5. Subject has a care partner who spends at least 15 hours/week with the patient, and can attend all visits with the patient, report accurately on the subject’s status and ensure compliance with all study requirements. 6. Subject and care partner (if necessary) must be willing and able to be admitted at the clinical research site as required by the study protocol. 7. Subject and care partner must each independently be able to understand the study requirements and provide informed consent. 8. Subject has either received an adequate dosing regimen of an approved SARS-CoV2 vaccine (according to current regional guidelines) at least 3 months prior to the anticipated first dose of study drug, or has recovered from SARS-CoV2, with evidence of persistent SARS-CoV2 serological response at the Screening visit. Nasal swabs or SARS-COVID-2 PCR may be obtained if required by local or institutional regulations. 9. Weight between 45 and 120 kg.

Subjects will be excluded from study participation if any one of the following exclusion criteria are met. 1. Females who are not postmenopausal at Screening as defined by amenorrhea for at least 12 consecutive months or who have not been sterilized surgically (i.e. bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before Screening). 2. Other than AD, neurologic or medical disorder which may impair cognition including: head trauma, seizure disorder, neurodegenerative disease, hydrocephalus, cerebral / spinal hematoma, inflammatory disease, CNS infection (e.g. encephalitis or meningitis), neoplasm, toxic exposure, metabolic disorder (including hypoxic or hypoglycaemic episodes), or endocrine disorder, or any significant medical conditions that, in the opinion of the Investigator, would prohibit their participation in the study. 3. As assessed by the central reader: a. Magnetic Resonance Imaging (MRI) evidence of a) more than three lacunar infarcts, b) territorial infarct or macroscopic haemorrhage, or c) deep white matter lesions corresponding to a Fazekas score > 3. b. Presence of any structural lesion that could potentially explain the subject’s cognitive impairment, or place the subject at risk for AEs during the trial. Examples include but are not limited to: cerebral contusion, encephalomalacia, aneurysm or vascular malformation, infective lesion, intraparenchymal tumor, meningioma or arachnoid cyst larger than 1 cm in longest diameter. 4. The combined number of Amyloid-Related Imaging Abnormalities-Haemorrhages (ARIA-H) (i.e. microbleeds and areas of leptomeningeal hemosiderosis on MRI) is more than 3 on a 1.5T scanner or more than 5 on a 3T scanner based on the review by the central reader. 5. Any contra-indication to undergo MRI, as judged by local PI or radiologist, including but not limited to presence of pacemaker, aneurysm clips, artificial heart valves, ear implants, ventriculoperitoneal shunt, foreign metal objects in the eyes, skin or body or any other circumstance which would contraindicate an MRI scan or impair MRI image quality, or history of claustrophobia or of not tolerating MRI scanning procedures. 6. Severe vision or hearing impairment that would prevent the subject from performing psychometric tests or otherwise complying with requirements for study participation and activities. 7. History of any of the following neurological, psychiatric or medical conditions: a. History of large vessel stroke. b. Transient Ischemic Attack (TIA) within 12 months of Screening visit. c. History of head trauma with documented loss of consciousness, evidence of parenchymal brain injury or skull fracture, or neurosurgical procedure. d. History of myocardial infarction or unstable angina within 12 months of the Screening visit. e. History of examination evidence of peripheral neuropathy or myopathy, whether or not of immune or presumed immune origin. f. Autoimmune disease (e.g. Systemic Lupus Erythematosus, Multiple Sclerosis, Rheumatoid arthritis, Type 1 diabetes mellitus). g. Immunocompromised systemically due to continuing effects of immunosuppressant medications other than topical steroids. h. Current or previous hepatitis B infection [defined as positive test for hepatitis B surface antigen (HbSAg) and/or hepatitis B core antibody (anti-HBc)]. Subjects with immunity to hepatitis B [if due to natural infection defined as negative HbSAg, positive hepatitis B antibody (anti-HBs) and positive anti-HBc; if due to vaccination defined as negative HbSAg, negative anti-HBc and positive anti-HBs] are eligible to participate in the study. i. History or positive test at Screening for hepatitis C virus (HCV) antibody. j. History or positive test at Screening for human immunodeficiency virus (HIV). k. Diagnosed with cancer with metastatic potential within the last 5 years other than carcinoma in situ of the breast or cervix, or basal cell carcinoma of the skin that has been completely excised. l. Major depressive disorder according to DSM-V criteria requiring initiation of medication or hospitalization within the previous 90 days. m. Systolic blood pressure > 160 mm Hg OR diastolic blood pressure > 95 mm Hg on three separate determinations 5 minutes apart, taken at same arm, after the patient feels comfortable and relaxed at the research facility. n. Clinically significant orthostatic hypotension. o. Presence of hallucinations or delusions. p. Active infection within 8 days of the first dosing visit. q. Surgery within 12 weeks of Screening. r. Blood donation of 1 unit or more within 8 weeks prior to the first dose of study medication. 8. Any of the following: a. Clinically significant (as determined by a cardiologist or central reader) 12-lead ECG abnormalities. b. Screening values for hemoglobin < 12 g/dL for men or < 11 g/dL for women. c. Any serum chemistry value (e.g. AST, ALT, Alkaline Phosphatase, total bilirubin etc.( > 1.5x the upper limit of normal on 2 successive determinations less than 2 weeks apart. d. eGFR < 50. e. Subjects with a bleeding disorder or at risk for increased or uncontrolled bleeding, including: i. Known bleeding disorder ii. Platelet count < 50,000, INR > 1.5 for subjects who are not on anti-coagulant treatment, or PTT not within the normal range f. Serum B12 clinically significantly below the lower limit of normal. 9. Presence of contraindication to lumbar puncture (LP) as judged by local PI, e.g. known X-ray or other evidence of significant lumbar spine abnormalities or history of lumbar surgery with sequalae that would interfere with or pose risks from the procedure; platelet count below 50,000 cells/mL; taking anticoagulant or antiplatelet medications other than aspirin at a dose of < 100 mg/day or clopidogrel (see item 11(h) below). 10. Any other significant medical conditions that, in the opinion of the Investigator, would prohibit participation in the study, including inability to tolerate the MRI scan, LP procedures or IV infusions. 11. Taking any of the following medications a. Antipsychotic agents, including pimavanserin. b. Stimulant medications (e.g., Ritalin, amphetamines). c. Antidepressant medications whose dose has not been stable for at least 90 days prior to Screening. d. Immunosuppressant medications, including chronic systemic corticosteroids (chronic use of topical steroids is allowed). e. Injected or infused antibody therapies, including but not limited to antibodies directed against TNF, anti-IL-6, natalizumab, rituximab and similar agents. f. Aducanumab, (aducanumab-avwa) intravenous injection (brand name: Aduhelm™), or any other experimental or approved anti-amyloid antibody. g. Insulin. h. Anticoagulant or anti-platelet medications including warfarin, heparinoids and direct coagulation factor inhibitors (e.g. apixaban, dabigatran, rivaroxaban) within 90 days of the planned first dose of study drug; either aspirin at a dose of < 100 mg/day or clopidogrel at a dose of 75 mg/day, but not both in combination is permitted. 12. Participation in any other interventional clinical trial, or treatment with any investigational drug or investigational use of an approved therapy, within 30 days or 5 half-lives of such agent, whichever is longer, prior to the first Screening visit. 13. Potential subject currently smokes more than 5 cigarettes or equivalent tobacco consumption daily. 14. Regular nonmedical use of cannabis or cannabis products unless such products are documented by the manufacturer’s label not to contain tetrahydrocannabinol or its derivatives or analogues. 15. History of drug (including cannabis) or alcohol abuse within the last 5 years. 16. Positive urine drug test for drugs of abuse at Screening. Potential subjects who test positive for benzodiazepines or opioids in urine drug testing need not be excluded if in the clinical opinion of the investigator, this is due to the subject taking prior/concomitant medications containing benzodiazepines or opioids for a medical condition and not due to drug abuse. 17. Potential subjects who answer "yes" to C-SSRS suicidal ideation Type 4 or 5, or any suicidal behavior assessment within 6 months before Screening, at Screening, or has been hospitalized or treated for suicidal behavior in the past 5 years before Screening. 18. Unwillingness to comply with study requirements or history of noncompliance in prior clinical trials.